Trial Profile
UARK 2003-25: A Phase I/II Open Label Study of IV Busulfan (Busulfex) in Multiple Myeloma Patients Older Than 65 Years of Age or With Renal Insufficiency.
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 18 Oct 2017
Price :
$35
*
At a glance
- Drugs Busulfan (Primary) ; Melphalan
- Indications Multiple myeloma
- Focus Adverse reactions
- 04 Mar 2011 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 29 Jun 2010 Actual patient number is 14 as reported by ClinicalTrials.gov.
- 29 Jun 2010 Actual end date (Oct 2009) added as reported by ClinicalTrials.gov.